Reduction of Nilutamide by NO Synthases: Implications for the Adverse Effects of This Nitroaromatic Antiandrogen Drug

Chemical Research in Toxicology

Volumn 16, Issue 12, 2003, Pages 1547-1554

  Ask, K ^a   Dijols, S ^b   Giroud, C ^b   Casse, L ^b   Frapart, Y M ^b   Sari, M A ^b   Kim, K S ^c   Stuehr, D J ^d   Mansuy, D ^b   Camus, P ^a   Boucher, J L ^b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Chonbuk National University   (South Korea)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ARGININE DERIVATIVE; AROMATIC NITRO COMPOUND; CALCIUM ION; CALMODULIN; CELL ENZYME; HEME; HYDROXYLAMINE; ISOPROTEIN; LIGAND; NILUTAMIDE; NITRIC OXIDE SYNTHASE; NITROREDUCTASE; OXIDOREDUCTASE; OXYGEN; QUERCETIN; RADICAL; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; BINDING AFFINITY; BIOSAFETY; CATALYSIS; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME PURIFICATION; MOLECULAR INTERACTION; NERVE CELL; PROTEIN DOMAIN; TOXICITY;

AMINES; ANAEROBIOSIS; ANDROGEN ANTAGONISTS; ANIMALS; CATTLE; ELECTRON SPIN RESONANCE SPECTROSCOPY; FREE RADICALS; IMIDAZOLES; IMIDAZOLIDINES; MICE; NADP; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATION-REDUCTION; RATS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 9144257253     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0340910     Document Type: Article

References (56)

1. Desai, A., Stadler, W. M., and Vogelzang, N. J. (2001) Nilutamide: Possible utility as a second-line hormonal agent. Urology 58, 1016-1020.
2. Yin, D., He, Y., Perera, M. A., Hong, S. S., Marhefka, C., Stourman, N., Kirkovsky, L., Miller, D. D., and Dalton, J. T. (2003) Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol. Pharmacol. 63, 211-223.
3. Mahler, C., Verhelst, J., and Denis, L. (1998) Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin. Pharmacokinet. 34, 405-417.
4. Creaven, P. J., Pendyala, L., and Tremblay, D. (1991) Pharmacokinetic and metabolism of nilutamide. Urology 37, 13-19.
5. Camus, P., Coudert, B., D'Athis, P., Foucher, P., Delchambre, J., Dupront, A., and Jeannin, L. (1991) Pharmacokinetics and metabolism of nilutamide in the isolated rat lung. J. Pharmacol. Exp. Ther. 259, 1247-1255.
6. Gomez, J. L., Dupont, A., Cusan, L., Tremblay, M., and Labrie, F. (1992) Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): A case report. Am. J. Med. 92, 563-566.
7. Gram, T. E. (1997) Chemically reactive intermediates and pulmonary xenobiotic toxicity. Pharmacol. Rev. 49, 297-341.
8. McLeod, D. G. (1997) Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 2, 18-27.
9. Babany, G., Tinel, M., Letteron, P., Freneaux, E., Berson, A., Larrey, D., and Pessayre, D. (1989) Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450. Biochem. Pharmacol. 38, 941-947.
10. Berson, A., Schmets, L., Fisch, C., Fau, D., Wolf, C., Fromenty, B., Deschamps, D., and Pessayre, D. (1994) Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this anti-androgen. J. Pharmacol. Exp. Ther. 270, 167-176.
11. Fau, D., Berson, A., Eugene, D., Fromenty, B., Fisch, C., and Pessayre, D. (1992) Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J. Pharmacol. Exp. Ther. 263, 69-77.
12. Berger, V., Berson, A., Wolf, C., Chachaty, C., Fau, D., Fromenty, B., and Pessayre, D. (1992) Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: Possible role in the development of lung lesions in patients treated with this antiandrogen. Biochem. Pharmacol. 43, 654-657.
13. Berson, A., Wolf, C., Berger, V., Fau, D., Chachaty, C., Fromenty, B., and Pessayre, D. (1991) Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide. J. Pharmacol. Exp. Ther. 257, 714-719.
14. Mason, R. P., and Holtzman, J. L. (1975) The mechanism of microsomal and mitochondrial nitroreductase. Electron spin resonance evidence for nitroaromatic free radical intermediates. Biochemistry 14, 1626-1632.
15. Reeve, I. T., and Miller, M. G. (2002) 1,3-Dinitrobenzene metabolism and protein binding. Chem. Res. Toxicol. 15, 352-360.
16. Reeve, I. T., Voss, J. C., and Miller, M. G. (2002) 1,3-Dinitrobenzene metabolism and GSH depletion. Chem. Res. Toxicol. 15, 361-366.
17. Eisenbrand, G., Muller, N., Denkel, E., and Sterzel, W. (1986) DNA adducts and DNA damage by antineoplastic and carcinogenic N-nitrosocompounds. J. Cancer Res. Clin. Oncol. 112, 196-204.
18. Ask, K., Heydel, J.-H., Piton, A., Foucher, P., Bonniaud, P., and Camus, P. (2000) Inducible nitric oxide synthase is implicated in the reductive metabolism of nilutamide in lung tissues. Nitric Oxide Biol. Chem. 4, 316.
19. Kerwin, J. F., Lancaster, J. R., and Feldman, P. L. (1995) Nitric oxide: A new paradigm for second messengers. J. Med. Chem. 38, 4343-4362.
20. Pfeiffer, S., Mayer, B., and Hemmens, B. (1999) Nitric oxide. Chemical puzzles posed by a biological messenger. Angew. Chem., Int. Ed. 38, 1714-1731.
21. Masters, B. S. S., McMillan, K., Sheta, E. A., Nishimura, J. S., Roman, L. J., and Martasek, P. (1996) Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: Structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO as a cellular signal. FASEB J. 10, 552-558.
22. Alderton, W. K., Cooper, C. E., and Knowles, R. G. (2001) Nitric oxide synthases: Structure, function and inhibition. Biochem. J. 357, 593-615.
23. Stuehr, D. J. (1999) Mammalian nitric oxide synthases. Biochim. Biophys. Acta 1411, 217-230.
24. Abu-Soud, H. M., Yoho, L. L., and Stuehr, D. J. (1994) Calmodulin controls neuronal nitric oxide synthase by a dual mechanism. J. Biol. Chem. 269, 32047-32050.
25. Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., and Snyder, S. H. (1991) Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351, 714-718.
26. Miyajima, M., Sagami, I., Daff, S., Migita, C. T., and Shimizu, T. (2000) Azo reduction of Methyl Red by neuronal nitric oxide synthase. The importance of FMN in catalysis. Biochem. Biophys. Res. Commun. 275, 752-758.
27. 2+/Calmodulin-dependent cytochrome c reductase activity of brain nitric oxide synthase. J. Biol. Chem. 267, 11374-11378.
28. Kumagai, Y., Nakajima, H., Midorikawa, K., Homma-Takeda, S., and Shimojo, N. (1998) Inhibition of nitric oxide formation by neuronal nitric oxide synthase by quinones: Nitric oxide synthase as a quinone reductase. Chem. Res. Toxicol. 11, 608-613.
29. Väsquez-Vivar, J., Martäsek, P., Hogg, N., Masters, B. S. S., Pritchard, K. A., and Kalyanaraman, B. (1997) Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36, 11293-11297.
30. Garner, A. P., Paine, M. J. I., Rodriguez-Crespo, I., Chinje, E. C., Ortiz de Montellano, P., Stratford, I. J., Tew, D. G., and Wolf, C. R. (1999) Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 59, 1929-1934.
31. Uetrecht, J. P., Sweetman, B. J., Woosley, R. L., and Oates, J. A. (1984) Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes. Drug Metab. Dispos. 12, 77-81.
32. Renodon, A., Boucher, J.-L., Sari, M.-A., Delaforge, M., Ouazzani, J., and Mansuy, D. (1997) Strong inhibition of neuronal nitric oxide synthase by the Calmodulin antagonist and anti-estrogen drug Tamoxifen. Biochem. Pharmacol. 54, 1109-1114.
33. Saiki, R. K., Gelfand D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., and Erlich, H. A. (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA ploymerase. Science 239, 487-491.
34. Sanger F., Nicklen S., and Coulson A. R. (1977). DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74, 5463-5467.
35. Hurshman, A. R., Krebs, C., Edmondson, D. E., Huynh, B. H., and Marletta, M. A. (1999) Formation of a pterin radical in the reaction of the heme domain of inducible nitric oxide synthase with oxygen. Biochemistry 38, 15689-15696.
36. Wu, C., Zhang, J., Abu-Soud, H., Ghosh, D. K., and Stuehr, D. J. (1996) High-level expression of mouse inducible nitric oxide synthase in Escherichia coli requires coexpression with calmodulin. Biochem. Biophys. Res. Commun. 222, 439-444.
37. Ghosh, S., Gachhui, R., Crooks, C., Wu, C., Lisanti, M. P., and Stuehr, D. J. (1998) Interaction between caveolin-1 and the reductase domain of endothelial nitric oxide synthase. J. Biol. Chem. 273, 22267-22271.
38. Abu-Soud, H.M., Gachhui, R., Raushel, F. M., and Stuehr, D. J. (1997) The ferrous-dioxy complex of neuronal nitric oxide synthase. Divergent effects of L-arginine and tetrahydrobiopterin on its stability. J. Biol. Chem. 272, 17349-17353.
39. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-252.
40. Bredt, D. S., and Snyder, S. H. (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. U.S.A. 87, 682-685.
41. Akaike, T., Yoshida, M., Miyamoto, Y., Sato, K., Kohno, M., Sasamoto, K., Miyazaki, K., Ueda, S., and Maeda, H. (1993) Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/NO through a radical reaction. Biochemistry 32, 827-832.
42. Entwistle, I. D., Gilkerson, T., Johnstone, R. A. W., and Telford, R. P. (1978) Rapid catalytic transfer reduction of aromatic nitro compounds to hydroxylamines. Tetrahedron 34, 213-215.
43. Workman, P. (1992) Bioreductive mechanisms. Int. J. Radiat. Oncol. Biol. Phys. 22, 631-637.
44. Santolini, J., Adak, S., Curran, C. M. L., and Stuehr, D. J. (2001) A kinetic simulation model that describes catalysis and regulation in nitric oxide synthase. J. Biol. Chem. 276, 1233-1243.
45. Gillette, J. R., Kamm, J. J., and Sasame, H. A. (1968) Mechanism of p-nitrobenzoate reduction in liver: The possible role of cytochrome P-450 in liver microsomes. Mol. Pharmacol. 4, 541-548.
46. Miller, R. T. (2002) Dinitrobenzene-mediated production of peroxynitrite by neuronal nitric oxide synthase. Chem. Res. Toxicol. 15, 927-934.
47. Huie, R. E., and Padmaja, S. (1993) The reaction of NO with superoxide. Free Radical Res. Commun. 18, 195-199.
48. Miller, R. T., Martasek, P., Omura, T., and Masters, B. S. S. (1999) Rapid kinetic studies of electron transfer in the three isoforms of nitric oxide synthase. Biochem. Biophys. Res. Commun. 265, 184-188.
49. Orna, M. V., and Mason, R. P. (1989) Correlation of kinetic parameters of nitroreductase enzymes with redox properties of nitroaromatic compounds. J. Biol. Chem. 264, 12379-12384.
50. Cenas, N., Nemeikaite-Ceniene, A., Sergediene, E., Nivinskas, H., Anusevicius, Z., and Sarlauskas, J. (2001) Quantitative structure-activity relationships in enzymatic single-electron reduction of nitroaromatic explosives: Implications for their cytotoxicity. Biochim. Biophys. Acta. 1528, 31-38.
51. Berson, A., Wolf, C., Chachaty, C., Fisch, C., Fau, D., Eugene, D., Loeper, J., Gauthier, J.-C., Beaune, P., and Pompon, D. (1993) Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J. Pharmacol. Exp. Ther. 265, 366-372.
52. Cossum, P. A., and Rickert, D. E. (1985) Metabolism of dinitrobenzenes by rat isolated hepatocytes. Drug Metab. Dispos. 13, 664-668.
53. MCeuen, S. F., and Miller, M. G. (1991) Metabolism and pharmacokinetics of 1,3-dinitrobenzene in the rat and the hamster. Drug Metab. Dispos. 19, 661-666.
54. Kedderis, G. L., and Miwa, G. T. (1988) The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab. Rev. 19, 33-62.
55. Weisburger, J. H., and Weiburger, K. W. (1973) Biochemical formation and pharmacological, toxicological and pathological properties of hydroxylamines and hydroxamic acids. Pharmacol. Rev. 25, 1-66.
56. Streeter, A. J., and Hoener, B. A. (1988) Evidence for the involvement of a nitrenium ion in the covalent binding of nitrofurazone to DNA. Pharm. Res. 5, 434-436.